Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
03:30pm, Wednesday, 08'th Apr 2020
Is (FATE) Outperforming Other Medical Stocks This Year?
2 Top U.S. Stocks to Watch in April
03:15pm, Wednesday, 08'th Apr 2020
These two stocks can be used to gauge how the pharmaceutical industry and energy sector are faring during the coronavirus pandemic -- and what might be ahead.
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results
02:41pm, Wednesday, 08'th Apr 2020
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
02:05pm, Wednesday, 08'th Apr 2020
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
02:05pm, Wednesday, 08'th Apr 2020
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?
02:04pm, Wednesday, 08'th Apr 2020
Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?
02:04pm, Wednesday, 08'th Apr 2020
Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fate Therapeutics Inc (NASDAQ:FATE) Shares Bought by Guggenheim Capital LLC
09:32am, Wednesday, 08'th Apr 2020
Guggenheim Capital LLC increased its stake in Fate Therapeutics Inc (NASDAQ:FATE) by 57.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The
Fate Therapeutics (NASDAQ:FATE) PT Lowered to $34.00
07:52am, Wednesday, 08'th Apr 2020
Fate Therapeutics (NASDAQ:FATE) had its price target dropped by stock analysts at Oppenheimer from $36.00 to $34.00 in a research report issued to clients and investors on Monday, BenzingaRatingsTable
Fate Therapeutics Inc (NASDAQ:FATE) Receives Average Rating of "Buy" from Analysts
05:58am, Wednesday, 08'th Apr 2020
Fate Therapeutics Inc (NASDAQ:FATE) has received an average recommendation of “Buy” from the nineteen brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stoc
Fate Therapeutics (NASDAQ:FATE) Shares Up 6.9% on Analyst Upgrade
05:06am, Wednesday, 08'th Apr 2020
Fate Therapeutics Inc (NASDAQ:FATE) shares shot up 6.9% on Monday after Piper Sandler raised their price target on the stock. The stock traded as high as $25.00 and last traded at $24.52, 801,539 shar
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
12:00am, Wednesday, 08'th Apr 2020My Top Biotech Stocks to Buy in the Market Crash
10:16am, Tuesday, 07'th Apr 2020
The worst is yet to come for the stock market, but these biopharma companies have promising potential.
Fate Therapeutics (NASDAQ:FATE) Price Target Increased to $41.00 by Analysts at Wedbush
10:00am, Tuesday, 07'th Apr 2020
Fate Therapeutics (NASDAQ:FATE) had its price objective upped by Wedbush from $38.00 to $41.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. The brokerage currently h
Cubist Systematic Strategies LLC Increases Stock Holdings in Fate Therapeutics Inc (NASDAQ:FATE)
09:22am, Tuesday, 07'th Apr 2020
Cubist Systematic Strategies LLC boosted its position in Fate Therapeutics Inc (NASDAQ:FATE) by 884,240.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund o
